Inactive Instrument

APTINYX

APTX

US03836N1037

Aptinyx Inc. Ratifies Selection of Deloitte & Touche LLP

May 31, 2022 at 04:45 pm EDT

Aptinyx Inc. ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.

Latest news about APTINYX

Aptinyx Inc. Approves Liquidating Cash Distribution, Payable on or About December 29, 2023	Dec. 18	CI
North American Morning Briefing : Concerns About -2-	23-09-07	DJ
North American Morning Briefing : PCE Inflation -2-	23-08-31	DJ
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
Aptinyx Inc. Announces Chief Executive Officer Changes	23-07-03	CI
Aptinyx Inc. Announces Management Changes	23-07-03	CI
Aptinyx Inc. Announces Principal Financial Officer Changes	23-07-03	CI
Aptinyx Inc. is Heading Towards Bankruptcy	23-05-23	CI
Aptinyx Inc.(OTCPK:APTX) dropped from S&P TMI Index	23-05-23	CI
Aptinyx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-18	CI
North American Morning Briefing : Stocks to Extend -3-	23-05-18	DJ
Aptinyx Inc.(OTCPK:APTX) dropped from NASDAQ Composite Index	23-05-18	CI
Aptinyx Inc. Announces Executive Changes	23-05-05	CI
Aptinyx Inc. Announces Departure of Ashish Khanna as Chief Financial Officer	23-05-05	CI
Aptinyx Inc. Announces Departure of Andy Kidd, Chief Executive Officer	23-05-05	CI
Aptinyx Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Aptinyx Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-30	CI
Aptinyx Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
North American Morning Briefing : Stock Futures -3-	23-03-08	DJ
HC Wainwright Downgrades Aptinyx to Neutral From Buy	23-03-07	MT
North American Morning Briefing : Rising Yields -3-	23-03-02	DJ
SVB Securities Downgrades Aptinyx to Market Perform From Outperform, Price Target is $0.50	23-03-01	MT
Aptinyx Inc. to Reduce its Workforce by Approximately 60%	23-03-01	CI
Top Premarket Decliners	23-02-28	MT

Aptinyx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The Company focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The Company's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The Company's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.

Sector

More about the company

APTINYX

Equities

APTX

US03836N1037

Aptinyx Inc. Ratifies Selection of Deloitte & Touche LLP

Latest news about APTINYX

Chart APTINYX

Company Profile